New Delhi, Oct 11 : The Delhi government’s Drugs Control Department has issued an official notice banning the sale, purchase, and distribution of Coldrif Syrup, after tests revealed that the formulation is adulterated and harmful to health.
In a notice dated October 10, the Department stated that Coldrif Syrup was declared “Not of Standard Quality” following a government analysis. The syrup was found to contain Diethylene Glycol (42.28% w/v), a toxic substance, making the drug injurious to health. Authorities have directed all stakeholders to immediately cease dealing with the syrup and urged the public to avoid its consumption.
The ban follows similar actions in other states. On October 7, Punjab prohibited the sale and use of Coldrif after 20 children reportedly died in Madhya Pradesh due to alleged contamination. Four other children are currently under treatment, according to Madhya Pradesh Deputy Chief Minister and Health Minister Rajendra Shukla.
The Drugs Controller General of India (DCGI) has also instructed all States and Union Territories to ensure strict compliance with the Drugs Rules, 1945, particularly emphasizing the testing of raw materials and finished formulations before production.
Details of the contaminated syrup are as follows: Drug Name: Coldrif Syrup (Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate); Batch Number: SR-13; Manufactured: May 2025; Expiry: April 2027; Manufacturer: Seesan Pharmaceutical, Sunguvachatram, Kancheepuram, Tamil Nadu.
Authorities reiterated that the syrup is unsafe and warned against its use, highlighting the critical need for vigilance in pharmaceutical testing and compliance.